Clinical trials
Moderately to Severely Active Crohns Disease clinical trials
Below are recruiting moderately to severely active crohns disease clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06637631RecruitingPhase 2
Testing an oral pill for moderate to severe Crohn's disease
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
Sun City, ArizonaAges 18–75 - NCT06958536RecruitingPhase 2
Testing a new drug for moderate to severe Crohn's disease
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Tucson, ArizonaAges 18–75 - NCT00692939RecruitingPhase 1/Phase 2
Stem cell transplant for people with Crohn’s who need new options
This trial studies whether an “autologous” stem cell transplant (using your own cells) can improve Crohn’s disease that has not responded to standard treatments. It may help people who have ongoing, hard-to-control Crohn’s even after medicines and/or who have complications that make surgery risky.
Pittsburgh, PennsylvaniaAges 10–60 - NCT07531342Recruiting
Brain Stimulation and Diet for Severe Crohn's Disease
This study tests whether repetitive transcranial magnetic stimulation (a non-invasive brain treatment) combined with an anti-inflammatory diet can help people with severe, treatment-resistant Crohn's disease feel better. The brain stimulation uses magnetic pulses on the scalp to reduce inflammation and improve symptoms.
Giza, Giza GovernorateAges 40–60 - NCT07556718RecruitingPhase 2
Amitriptyline for IBS-like Symptoms in Stable Crohn's Disease
This study tests whether a medication called amitriptyline can help reduce belly pain and bowel problems in people whose Crohn's disease is well-controlled. Amitriptyline is an older antidepressant that may help with pain and bowel symptoms even when inflammation is quiet.
Ann Arbor, MichiganAges 18–65 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Scottsdale, ArizonaAges 18–80 - NCT07427017RecruitingPhase 2
Selenium for Ulcerative Colitis Patients on Biologics
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Chicago, IllinoisAges 18–85 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Phoenix, ArizonaAges 2–17 - NCT07487480Recruiting
Guselkumab for Crohn's after ustekinumab
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06469424Recruiting
Safety of Tofacitinib in Ulcerative Colitis
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
BonheidenAges 18 years+ - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Scottsdale, ArizonaAges 18–80 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Phoenix, ArizonaAges 2–17 - NCT06029972RecruitingPhase 2
Experimental drug for moderate to severe ulcerative colitis
This trial tests an experimental medication (tilpisertib fosmecarbil) for people with moderate to severe ulcerative colitis who have already tried at least one advanced therapy but it didn't work well enough. The study aims to see if this new drug can help reduce inflammation and improve symptoms.
Sun City, ArizonaAges 18–75 - NCT06598943RecruitingPhase 2
Study of two new drugs for ulcerative colitis
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
Chandler, ArizonaAges 18–75 - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07083193RecruitingPhase 1/Phase 2
Study of AC-101 tablets for moderate to severe ulcerative colitis
This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.
Guangzhou, GuangdongAges 18–75 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Mobile, AlabamaAges 2 years+ - NCT07093294Recruiting
Predicting vedolizumab success with ultrasound in early Crohn's
This study uses intestinal ultrasound to see if vedolizumab can heal the gut in people recently diagnosed with Crohn's disease. It aims to find early signs that the treatment is working.
Changsha, HunanAges 18–80
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active crohns disease?
- Yes. Clin2 currently lists 87 recruiting moderately to severely active crohns disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active crohns disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active crohns disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.